FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20049

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>ALDRICH RICHARD</u>						2. Issuer Name <b>and</b> Ticker or Trading Symbol KalVista Pharmaceuticals, Inc. [ KALV ]								Relationship neck all appli	cable) or	g Pers	10% Ov	vner
(Last) C/O LOI	(Last) (First) (Middle) C/O LONGWOOD FUND MANAGEMENT LLC					3. Date of Earliest Transaction (Month/Day/Year) 09/27/2017								Officer (give title Other (specify below) below)				specify
PRUDENTIAL TOWER, 800 ROYLSTON STREET, S				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)				-									X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(Si	tate)	(Zip)															
		Tab	le I - Nor	-Deriv	ative	Se	curitie	s Ac	quired, D	ispo	sed c	f, or Be	neficial	ly Owne	k			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)						ar)   i	2A. Deemed Execution Date, if any (Month/Day/Year		Transaction Dispose Code (Instr. 5)		rities Acquired (A) ed Of (D) (Instr. 3, 4		Benefic	es ally Following	Form (D) or	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	/ A	Amount (A) or (D)		r Price	Transac	nsaction(s) str. 3 and 4)				
		7							uired, Dis s, options					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	Code (In				6. Date Exercisable Expiration Date (Month/Day/Year)		e and	nd 7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	e O' s Fo llly Di or (1)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Expii Date	iration	Title	Amount or Number of Shares					
Director Stock Option (Right to Buy)	\$6.71	09/27/2017			A		6,000		(1)	09/26	6/2027	Common Stock	6,000	\$0	6,000		D	

## **Explanation of Responses:**

1. The option vests over a 12 month period: 1/12th on October 27, 2017, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date.

/s/Benjamin Palleiko,

09/29/2017

Attorney-in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.